Surgical Oncology Insight最新文献

{"title":"Trends in surgical treatment of stage IV melanoma: A SEER database study.","authors":"Orly N Farber, Yu-Jen Chen, George Molina, Olivia Monton, Elizabeth J Lilley","doi":"10.1016/j.soi.2025.100176","DOIUrl":"10.1016/j.soi.2025.100176","url":null,"abstract":"<p><strong>Introduction: </strong>Immunotherapy for advanced melanoma has improved survival outcomes and changed the surgical management of this disease. Prior work demonstrated no difference in rates of resection for stage IV melanoma after the introduction of immunotherapy. However, prior data were limited by shorter study durations and by only examining distant resections. As such, we sought to expand this work by examining longitudinal trends in both primary and distant resections for patients with advanced melanoma in the years after immunotherapy approvals.</p><p><strong>Methods: </strong>This retrospective cohort study used the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) database to capture adult patients diagnosed with stage IV cutaneous melanoma between 2004 and 2020. We identified the annual percentage of patients who underwent surgical resections.</p><p><strong>Results: </strong>Of the 10,632 case records included, significantly fewer patients underwent surgical resection in the post-immunotherapy era (2011-2020) as compared to the pre-immunotherapy era (2004-2013) (50.4 % vs. 59.6 %, p < 0.0001). In our interrupted time series, we found a significant decline in the rate of all surgical resections in the post-immunotherapy era, decreasing by 0.97 % per year (p < 0.0001). There were significant decreases in the rates of both primary and distant resections in the post-immunotherapy era. For primary resections alone, we observed a significant level of change with annual rates of surgery declining by 5.1 % (p = 0.014) after 2011.</p><p><strong>Conclusions: </strong>This study confirms that a significant - albeit declining - proportion of patients with stage IV melanoma undergo both primary and distant resections in the post-immunotherapy era.</p><p><strong>Synopsis: </strong>Since the initial approval of immunotherapy to treat advanced melanoma in 2011, the role of surgical care for melanoma has evolved. This study examined trends in the utilization of surgery for patients with stage IV melanoma before and after 2011. We identified patients diagnosed with stage IV melanoma between 2004 and 2020 (N = 10,632) from the Surveillance, Epidemiology, and End Results database. Using an interrupted time series analysis, we compared the proportion of patients who underwent either primary or distant surgical resections in the pre- and post-immunotherapy eras (59.6 % vs. 50.4 %, respectively; p < 0.0001). There was a significant decline in the rate of all surgical resections in the post-immunotherapy era, decreasing by 0.97 % per year (p < 0.0001). These results highlight diminishing but still robust surgical treatment of stage IV melanoma since the introduction of immunotherapy.</p>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"2 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12431681/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145066988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dissecting the PRADO (Personalized Response-driven ADjuvant cOmbination therapy) trial in melanoma for surgical oncologists; safety and feasibility of surgical de-escalation after neo-adjuvant immunotherapy for macroscopic stage III melanoma","authors":"Charlotte M.C. Oude Ophuis ,&nbsp;Alexander C.J. van Akkooi","doi":"10.1016/j.soi.2025.100186","DOIUrl":"10.1016/j.soi.2025.100186","url":null,"abstract":"<div><div>The Personalized Response-directed surgery and Adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma (PRADO trial) is an international, multicenter, single arm, non-randomized prospective phase 2 trial that investigated neoadjuvant immunotherapy (ipi-nivo) in patients with macroscopic stage III melanoma. Depending on tumor response after index lymph node resection (ILN), patients were offered follow up only (major pathologic response, MPR ≤10 % viable melanoma); therapeutic lymph node dissection (TLND) without adjuvant therapy (partial pathologic response, pPR; 11–50 % viable tumor cells), and finally, TLND + /- adjuvant radiotherapy to the nodal field, followed by adjuvant systemic therapy (pathologic non response (pNR; &gt;50 % viable tumor cells), and switch to BRAF/MEK inhibition in case of a BRAF V600 mutation. Primary endpoints were confirmation of pathologic response rate (pRR) of the ipi-nivo; to investigate whether TLND can be safely omitted in patients achieving MPR, with the hypothesis that MPR is durable and transcends the need for TLND. Results showed that MPR could be achieved 61 % of patients and TLND could safely be omitted in these patients with significantly lower surgical morbidity and better QoL, with durable DFS and DMFS at 2 years. Summarizing, the PRADO trial showed that in macroscopic stage III melanoma 2 doses of neoadjuvant ipi-nivo leads to a high MPR rate and suggests TLND can be safely omitted in favor of ILN. Validation of this concept will follow in MSLT-3.</div></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"2 4","pages":"Article 100186"},"PeriodicalIF":0.0,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145027467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phase 1 dose escalation trial of vv-DD-hIL-2-RG-1 (vaccinia virus double deleted) administration by intratumoral injection for metastatic gastrointestinal tumors: The regional immuno-oncology trial - 3 (RIOT-3) protocol","authors":"Brett M. Szeligo ,&nbsp;Shannon Altpeter ,&nbsp;Catherine Lewis ,&nbsp;Albert D. Donnenberg ,&nbsp;Christopher Sherry ,&nbsp;Vera S. Donnenberg ,&nbsp;Paige Mirsky ,&nbsp;Neda Dadgar ,&nbsp;Ali Zaidi ,&nbsp;Nathan Bahary ,&nbsp;Zuqiang Liu ,&nbsp;David L. Bartlett ,&nbsp;Patrick L. Wagner","doi":"10.1016/j.soi.2025.100185","DOIUrl":"10.1016/j.soi.2025.100185","url":null,"abstract":"<div><div>Current treatments for metastatic gastrointestinal malignancies have poor outcomes, necessitating a novel approach to treatment. Oncolytic therapy with vaccinia viruses has previously shown promising results in terms of safety and anti-tumor efficacy. In addition to direct viral cytotoxic effects, oncolytic therapy has the potential to stimulate adaptive immunity against infected tumor cells by altering the tumor microenvironment. The immunostimulatory effects of oncolytic vaccinia vectors have been maximized through the use of recombinant vectors encoding interleukin-2 (IL-2), a potent cytokine that signals T cell activity and proliferation. This report details the use of a novel oncolytic vaccinia vector-- vvDD-hIL-2-RG-1—which encodes a rigid peptide-linked, membrane-bound form of IL-2, designed to maximize the local immunomodulatory activity following intra-tumoral injection.</div><div>RIOT-3 is a phase 1, open-label, single-dose, dose-escalation trial investigating intratumoral injection of vvDD-hIL-2-RG-1. Up to 18 participants with metastatic gastrointestinal cancer who have failed systemic chemotherapy or immunotherapy will be enrolled. The primary study objective is to determine the safety and maximal tolerated and feasible doses for intratumoral injection via a 3 + 3 dose escalation design. Secondary objectives include quantifying viral replication, pharmacokinetics, and immune response to vvDD-hIL-2-RG-1 intratumoral injection, as well as efficacy assessment by RECIST criteria.</div><div>Previous preclinical data in a murine model have demonstrated that IL-2-bound vaccinia oncolytic virus is safe and exerts dose-dependent anti-tumor activity. RIOT-3 will explore the application of this novel oncolytic viral approach in patients with advanced gastrointestinal malignancies who have failed conventional therapies. The trial is registered at ClinicalTrials.gov; NCT07001592 (registered May 6th, 2025).</div></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"2 3","pages":"Article 100185"},"PeriodicalIF":0.0,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144917863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pulmonary metastases, colorectal cancer, and survival: Accurate interpretation of the literature","authors":"By Tom Treasure,&nbsp;Fergus Macbeth","doi":"10.1016/j.soi.2025.100187","DOIUrl":"10.1016/j.soi.2025.100187","url":null,"abstract":"","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"2 3","pages":"Article 100187"},"PeriodicalIF":0.0,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144917864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A single arm, prospective, open label, multicenter study assessing the safety and effectiveness of SPY AGENT GREEN and SPY fluorescence imaging systems in the visualization of lymphatic vessels and lymph nodes during lymphatic mapping and sentinel lymph node biopsy in subjects with breast cancer","authors":"David C. Weintritt ,&nbsp;Beth-Ann Lesnikoski ,&nbsp;Michelle E. Goecke ,&nbsp;Christine Desbiens ,&nbsp;Alicia K. Wilton ,&nbsp;Allison A. DiPasquale ,&nbsp;Sommer R. Gunia","doi":"10.1016/j.soi.2025.100184","DOIUrl":"10.1016/j.soi.2025.100184","url":null,"abstract":"<div><h3>Background</h3><div>Sentinel Lymph Node Biopsy (SLNB) using technetium-99m (Tc-99m) is standard for axillary staging in early-stage breast cancer. Indocyanine green (ICG) is an alternative method with meta-analyses reporting clinical effectiveness of ICG comparable or superior to Tc-99m.</div></div><div><h3>Methods</h3><div>This prospective study evaluated the safety and effectiveness of SPY Portable Handheld Imaging System (SPY-PHI)/SPY AGENT GREEN (SAG) in the identification of histology confirmed lymph nodes (LN). Patients were administered Tc-99m per institutional protocol and SAG intradermally in the peri-areolar area. LNs were subsequently identified/excised under intraoperative fluorescence, then assessed for radioactivity using a gamma probe. Effectiveness of nodal detection was determined by comparing the proportion of LNs identified by SAG to the proportion identified by Tc-99m. Effectiveness of per subject LN identification, intraoperative fluorescence visualization of lymphatic vessels, and safety of intradermal injection of SAG were also evaluated.</div></div><div><h3>Results</h3><div>One hundred fifty-one subjects completed the study and follow-up. Lymphatic mapping/SLNB were unsuccessful with either technique in 3 subjects, resulting in 148 evaluable subjects. SPY-PHI/SAG identified 89 % (360/406) of LNs while Tc-99m identified 66 % (266/406). For both methods the per patient identification rate was 98 % (145/148). These results demonstrate SPY-PHI/SAG was non-inferior to Tc-99m (p-value &lt;0.0001). SPY-PHI/SAG provided visualization of lymphatic flow confirming mapping and aiding in identification of 99 % (357/360) of SPY-PHI/SAG identified LNs. Forty metastatic LNs were confirmed in 29 subjects. At least one metastatic LN was detected in 93 % of these subjects using SPY-PHI/SAG versus 83 % using Tc-99m. There were no adverse events related to SPY-PHI/SAG.</div></div><div><h3>Conclusions</h3><div>SPY-PHI/SAG are an effective modality for visualizing and identifying lymphatic nodes and vessels in early-stage breast cancer.</div></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"2 4","pages":"Article 100184"},"PeriodicalIF":0.0,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145011308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Littoral cell angioma unveiled: Exploring diagnosis, treatment, and malignant potential","authors":"Caitlin Blades ,&nbsp;Vivian Duarte ,&nbsp;Aline Hikari Ishida ,&nbsp;David Pfau ,&nbsp;Nikhil Madhuripan ,&nbsp;Patrick Henn ,&nbsp;Benedetto Mungo ,&nbsp;Martin McCarter ,&nbsp;Ana Gleisner ,&nbsp;Sumaya Abdul Ghaffar","doi":"10.1016/j.soi.2025.100178","DOIUrl":"10.1016/j.soi.2025.100178","url":null,"abstract":"<div><h3>Introduction</h3><div>Littoral cell angioma (LCA) is a rare vascular tumor of the spleen that is mostly benign but has malignant potential. Differentiating between these forms is challenging and relies on surgical pathology for final diagnosis, with splenectomy serving as both a diagnostic and curative measure. As metastatic LCA is exceedingly rare, limited data on treatment and follow-up is available in the existing literature.</div></div><div><h3>Methods</h3><div>A retrospective review of LCA cases treated at our institution from 2000 to 2023 was conducted. A comprehensive literature review was also performed to assess treatment options, long-term follow-up, and prognosis for malignant LCA.</div></div><div><h3>Results</h3><div>The cohort included six patients, with a mean age of 67 years. Two-thirds of cases were incidentally diagnosed. Five patients underwent splenectomy. Pathological examination revealed splenomegaly in two-thirds of the cohort. One patient developed liver and retroperitoneal metastases six years post-splenectomy. Pazopanib was chosen as the first-line treatment following consultation with a multidisciplinary team. After six months of daily Pazopanib, the patient exhibited reduced lymphadenopathy and stable disease in the liver. A literature review identified seven cases of metastatic LCA, predominantly focusing on diagnosis and revealing a gap in information on treatment regimens, follow-up strategies, and prognosis.</div></div><div><h3>Conclusion</h3><div>LCA presents significant diagnostic and therapeutic challenges, particularly in metastatic cases. For those, these findings suggest the need for extended follow-up beyond the conventional five-year cancer benchmark and individualized treatment approaches. Reporting metastatic and other complex LCA cases is crucial for enhancing the literature and guiding healthcare providers in managing this rare disease.</div></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"2 3","pages":"Article 100178"},"PeriodicalIF":0.0,"publicationDate":"2025-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144830320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bridging the gap: Addressing gastric cancer disparities among Korean Americans through insights from South Korea","authors":"Minji Kwon,&nbsp;Asher J Shin,&nbsp;Ji Hyun Hong,&nbsp;Cameron J. Sabet,&nbsp;Edward Christopher Dee,&nbsp;Peter Ko","doi":"10.1016/j.soi.2025.100177","DOIUrl":"10.1016/j.soi.2025.100177","url":null,"abstract":"","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"2 3","pages":"Article 100177"},"PeriodicalIF":0.0,"publicationDate":"2025-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144863382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current status of intraoperative radiation therapy in rectal cancer: A national cancer database analysis","authors":"Amulya Vadlakonda ,&nbsp;Sara Sakowitz ,&nbsp;Nikhil Chervu ,&nbsp;Konmal Ali ,&nbsp;Troy Coaston ,&nbsp;Luigi Pianetti ,&nbsp;Peyman Benharash ,&nbsp;Aimal Khan ,&nbsp;Hanjoo Lee","doi":"10.1016/j.soi.2025.100175","DOIUrl":"10.1016/j.soi.2025.100175","url":null,"abstract":"<div><h3>Background</h3><div>Intraoperative radiotherapy (IORT) is used to target the tumor bed and threatened margin and evolved into a dose escalation technique in the treatment of rectal cancer. Given the limited use of IORT in specialized centers, we analyzed a national database to characterize temporal trends and utilization patterns for this treatment modality.</div></div><div><h3>Methods</h3><div>All adults (≥18 years) undergoing proctectomy for T3/4, any N rectal adenocarcinoma were identified in the 2004–2020 NCDB. Patients were stratified into those who received IORT and those who didn’t. Cuzick’s nonparametric test was used to assess the significance of temporal trends.</div></div><div><h3>Results</h3><div>Of 72,654 patients eligible for analysis, 137 (0.2 %) underwent IORT. 81 % of patients with IORT underwent resection with microscopically confirmed negative margin. There was no significant rise in utilization of IORT during the study period (nptrend=0.10). Of a total 1314 hospitals included in the study, 54 (4.1 %) performed IORT, with a cumulative volume ranging from 1 to 15 cases over the study period.</div></div><div><h3>Conclusions</h3><div>We note a significant variability in IORT practices with treatment primarily offered to patients with margin-negative resection. We found that only a small fraction of institutions performed IORT with no change in its utilization during the study period. Our findings underscore the need to reassess the utility of IORT in the contemporary era and call for improving current guidelines.</div></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"2 3","pages":"Article 100175"},"PeriodicalIF":0.0,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144827606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Total neoadjuvant therapy (TNT) improves completion rates of intended therapy and oncologic outcomes in locally advanced gastric cancer","authors":"EeeLN Buckarma ,&nbsp;Shelby Yee ,&nbsp;Robert A. Vierkant ,&nbsp;Emily Siegler ,&nbsp;Mojun Zhu ,&nbsp;Cornelius Thiels ,&nbsp;Mark Truty ,&nbsp;Michael Kendrick ,&nbsp;Travis E. Grotz","doi":"10.1016/j.soi.2025.100173","DOIUrl":"10.1016/j.soi.2025.100173","url":null,"abstract":"<div><h3>Background</h3><div>Perioperative chemotherapy (PC) is the standard for locally advanced gastric cancer (LAGC) but can be difficult to implement with many patients unable to complete adjuvant therapy. Total neoadjuvant therapy (TNT) may result in improved adherence and outcomes.</div></div><div><h3>Methods</h3><div>Single institution retrospective review of LAGC treated with chemotherapy and surgery (2008–2023). Therapy strategy, clinical, pathological, and perioperative outcomes were examined using multivariable regression. Kaplan-Meier curves and cox proportional hazards regression models were used for recurrence free survival (RFS) and (OS).</div></div><div><h3>Results</h3><div>202 patients included, 71(35 %) were treated with TNT and 131(65 %) PC. No differences in baseline demographics. TNT patients received more cycles of treatment (median 8, IQR 6–9) compared to PC (median 6, IQR 4–8) (p &lt; 0.001). 66 % of PC patients-initiated adjuvant chemotherapy and 46 % of those patients completed ≥ 3 cycles. There was no significant difference in postoperative morbidity between TNT and PC. There were similar (20 % vs 22 %) rates of pathologic complete response and margin negative resections (99 % vs 98 %). TNT approach was associated with improved 18-month RFS and five-year OS on univariate analysis. 94 % TNT patients received ≥ 6 cycles of chemotherapy compared to PC (50 %), p = 0.002. Patients who received ≥ 6 cycles of chemotherapy were found to have improved 18-month RFS and 5-year OS when compared to those who received ≤ 4 (RFS HR=2.93, 95 %CI 1.59–5.41, p &lt; 0.001, OS HR=2.32, 95 %CI 1.39–3.92, p = 0.002).</div></div><div><h3>Conclusion</h3><div>TNT strategy for LAGC results in a higher rate of completing intended therapy. The completion of ≥ 6 cycles of chemotherapy were independently associated with improved RFS and OS.</div></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"2 3","pages":"Article 100173"},"PeriodicalIF":0.0,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144827605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing the ability of Timed Up and Go and Modified Frailty Index-5 compared to Fried frailty index to objectively identify frail patients undergoing evaluation for surgery","authors":"Gregory Palmateer ,&nbsp;William Luke ,&nbsp;Adam Braunschweig ,&nbsp;Benjamin Schmeusser ,&nbsp;Eric Midenberg ,&nbsp;Dattaraya Patil ,&nbsp;Nahar Imtiaz ,&nbsp;Samay Patel ,&nbsp;Susan Mumford ,&nbsp;Ethan Kearns ,&nbsp;Khushali Vashi ,&nbsp;Mohammad Hajiah ,&nbsp;Valentina Grajales ,&nbsp;Shreyas S. Joshi ,&nbsp;Vikram M. Narayan ,&nbsp;Kenneth Ogan ,&nbsp;Viraj A. Master","doi":"10.1016/j.soi.2025.100183","DOIUrl":"10.1016/j.soi.2025.100183","url":null,"abstract":"<div><h3>Introduction</h3><div>Frailty is associated with worsened perioperative outcomes, and well studied tools like the Fried Frailty Index are impractical in busy clinical settings. This study evaluated the utility of clinic administered Timed Up &amp; Go (TUG) test and the modified frailty index-5 (MFI-5) in identifying frail patients prior to urologic surgery.</div></div><div><h3>Methods</h3><div>We retrospectively analyzed data from 106 patients in with concurrent Fried, TUG, and MFI-5 scores. Spearman’s rank correlation assessed relationships among measures, and diagnostic accuracy was used to identify optimal cutoffs.</div></div><div><h3>Results</h3><div>Of the cohort, 38.7 % were frail as measured by the gold standard Fried Frailty Index, TUG and MFI-5 scores were significantly higher in frail patients. TUG showed moderate correlation with Fried frailty achieving an area under the curve (AUC) of 0.794, while MFI-5 was mildly correlated with an AUC of 0.612. A TUG ≥ 11 s and MFI-5 ≥ 0.3 offered the highest classification accuracy.</div></div><div><h3>Conclusions</h3><div>TUG better correlated with Fried frailty status than MFI-5 with a TUG ≥ 11 s best predicting frailty in our cohort.</div></div><div><h3>Synopsis</h3><div>Fried frailty predicts poor surgical outcomes but is impractical to assess. Among urologic cancer patients, Timed Up and Go (TUG) moderately correlated with Fried frailty and may offer a practical, objective, and reliable alternative for measuring frailty.</div></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"2 3","pages":"Article 100183"},"PeriodicalIF":0.0,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144863268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}